CHRONIC OBSTRUCTIVE PULMONARY DISEASE Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I

Background: Chronic obstructive pulmonary disease (COPD) is often associated with peripheral muscle weakness, which is caused by several factors. Acute exacerbations may contribute, but their impact on muscle force remains unclear. Correlations between peripheral muscle force and inflammatory and anabolic markers have never been studied in COPD. The effect of an acute exacerbation on quadriceps peak torque (QPT) was therefore studied in hospitalised patients, and the aforementioned correlations were examined in hospitalised and in stable patients. Methods: Lung function, respiratory and peripheral muscle force, and inflammatory and anabolic markers were assessed in hospitalised patients on days 3 and 8 of the hospital admission and 90 days later. The results on day 3 (n=34) were compared with those in clinically stable outpatients (n=13) and sedentary healthy elderly subjects (n=10). Results: Hospitalised patients had lowest mean (SD) QPT (66 (22)% predicted) and highest median (IQR) levels of systemic interleukin-8 (CXCL8, 6.1 (4.5 to 8.3) pg/ml). Insulin-like growth factor I (IGF-I) tended to be higher in healthy elderly subjects (p=0.09). QPT declined between days 3 and 8 in hospital (mean −5% predicted (95% CI −22 to 8)) and partially recovered 90 days after admission to hospital (mean 6% predicted (95% CI −1 to 23)). QPT was negatively correlated with CXCL8 and positively correlated with IGF-I and lung transfer factor in hospitalised and in stable patients. Conclusions: Peripheral muscle weakness is enhanced during an acute exacerbation of COPD. CXCL8 and IGF-I may be involved in the development of peripheral muscle weakness in hospitalised and in stable patients with COPD.

[1]  A. Kenny,et al.  Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[2]  Y. Lacasse,et al.  Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[3]  H. Westerblad,et al.  Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. , 2002, American journal of respiratory and critical care medicine.

[4]  M. Decramer,et al.  Resistance versus endurance training in patients with COPD and peripheral muscle weakness , 2002, European Respiratory Journal.

[5]  G. Verleden,et al.  What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? , 2002, European Respiratory Journal.

[6]  A. Newman,et al.  Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[7]  G. Schuler,et al.  Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[8]  F. Martinez,et al.  Acute Exacerbations of Chronic Obstructive Pulmonary Disease , 2013 .

[9]  C. Hart,et al.  Myositis in children with meningococcal disease: a role for tumour necrosis factor-alpha and interleukin-8? , 2002, The Journal of infection.

[10]  M. Blackman,et al.  Comparison of GH, IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men. , 2001, American journal of physiology. Endocrinology and metabolism.

[11]  A. Ionescu,et al.  Inflammatory response and body composition in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[12]  L. Fried,et al.  Association of IGF-I levels with muscle strength and mobility in older women. , 2001, The Journal of clinical endocrinology and metabolism.

[13]  E. Wouters,et al.  Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations , 2001, Thorax.

[14]  F. Graziano,et al.  Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. , 2001, Journal of immunological methods.

[15]  S. Anker,et al.  High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. , 2001, Cytokine.

[16]  E. Bozkanat,et al.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease , 2001, Respiratory research.

[17]  U. Tylén,et al.  Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT. , 2001, Respiratory medicine.

[18]  I. Waddell,et al.  Proteolysis‐inducing factor regulates hepatic gene expression via the transcription factors NF‐κΒ and STAT3 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  R. Casaburi Skeletal muscle dysfunction in chronic obstructive pulmonary disease. , 1999, Medicine and science in sports and exercise.

[20]  M. Decramer The respiratory rehabilitation division of the University Hospital Gasthuisberg, Leuven, Belgium , 2001 .

[21]  P. Barnes Potential novel therapies for chronic obstructive pulmonary disease. , 2001, Novartis Foundation symposium.

[22]  T. Seemungal,et al.  Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels , 2000, Thrombosis and Haemostasis.

[23]  T. Seemungal,et al.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[24]  E. Wouters,et al.  Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[25]  N. Hopkinson,et al.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. , 2009, American journal of respiratory and critical care medicine.

[26]  F. Maltais,et al.  Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[27]  P. Poole‐Wilson,et al.  Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. , 1998, Journal of the American College of Cardiology.

[28]  R. Schwartz,et al.  Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α , 1998 .

[29]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[30]  J. Govan,et al.  Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. , 1998, Respiratory medicine.

[31]  R. Schwartz,et al.  Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  E. Wouters,et al.  Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. , 1997, The European respiratory journal.

[33]  W. MacNee,et al.  Prognostic significance of plasma D-dimer levels in patients with lung cancer. , 1997, Thorax.

[34]  M. Decramer,et al.  Muscle weakness is related to utilization of health care resources in COPD patients. , 1997, The European respiratory journal.

[35]  E. Wouters,et al.  Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. , 1996, Thorax.

[36]  J. Crowley,et al.  Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. , 1996, American journal of respiratory and critical care medicine.

[37]  M. Decramer,et al.  Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[38]  M. Decramer,et al.  Peripheral muscle weakness contributes to exercise limitation in COPD. , 1996, American journal of respiratory and critical care medicine.

[39]  K. Fearon,et al.  Characterization of a cancer cachectic factor , 1996, Nature.

[40]  R. Rogers,et al.  Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. , 1996, American journal of respiratory and critical care medicine.

[41]  M. Polkey,et al.  Quadriceps strength and fatigue assessed by magnetic stimulation of the femoral nerve in man , 1995, Muscle & nerve.

[42]  M. Decramer,et al.  Corticosteroids contribute to muscle weakness in chronic airflow obstruction. , 1994, American journal of respiratory and critical care medicine.

[43]  N. Agell,et al.  Tumour necrosis factor‐α increases the ubiquitinization of rat skeletal muscle proteins , 1993 .

[44]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[45]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[46]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[47]  N. Agell,et al.  Tumour necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. , 1993, FEBS letters.

[48]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[49]  Flick Da,et al.  Pharmacokinetics of murine tumor necrosis factor. , 1986 .

[50]  D. A. Flick,et al.  Pharmacokinetics of murine tumor necrosis factor. , 1986, Journal of immunopharmacology.

[51]  V. Mathiowetz,et al.  Grip and pinch strength: normative data for adults. , 1985, Archives of physical medicine and rehabilitation.

[52]  Müller Ea,et al.  Influence of training and of inactivity on muscle strength. , 1970 .

[53]  E. Müller,et al.  Influence of training and of inactivity on muscle strength. , 1970, Archives of physical medicine and rehabilitation.

[54]  L. F. Black,et al.  Maximal respiratory pressures: normal values and relationship to age and sex. , 2015 .